Results 31 to 40 of about 8,113 (209)

Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption

Drug Delivery, 2017
Bosentan is an endothelin receptor antagonist (ERA) prescribed for patients with pulmonary arterial hypertension (PAH). The oral delivery of bosentan possesses several drawbacks such as low bioavailability (about 50%), short duration of action, frequent ...
Lydia A. Hanna, Emad B. Basalious, Omaima N. ELGazayerly   +2 more
doaj   +1 more source

A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy

Molecular Cancer, 2010
Background The endothelin system is implicated in the pathogenesis of melanoma. We evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV metastatic cutaneous melanoma
Ballmer Andrea, Brady Benjamin, Clingan Philip R, Kefford Richard F, Morganti Adele, Hersey Peter   +5 more
doaj   +1 more source

A non-selective endothelin receptor antagonist bosentan modulates kinetics of bone marrow-derived cells in ameliorating pulmonary hypertension in mice

Pulmonary Circulation, 2020
The aim of this study was to investigate whether a dual endothelin receptor antagonist bosentan modulates the kinetics of bone marrow-derived stem cells in inhibiting the development of pulmonary hypertension. Bone marrow chimeric mice, transplanted with
Taichi Kato, Yoshihide Mitani, Masahiro Masuya, Junko Maruyama, Hirofumi Sawada, Hiroyuki Ohashi, Yukiko Ikeyama, Shoichiro Otsuki, Noriko Yodoya, Tsutomu Shinohara, Eri Miyata, Erquan Zhang, Naoyuki Katayama, Hideto Shimpo, Kazuo Maruyama, Yoshihiro Komada, Masahiro Hirayama   +16 more
doaj   +1 more source

Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta‐Analysis of 4894 Patients From 24 Randomized Double‐Blind Placebo‐Controlled Clinical Trials

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundEvidence of the clinical safety of endothelin receptor antagonists (ERAs) is limited and derived mainly from individual trials; therefore, we conducted a meta‐analysis.
Anhua Wei, Zhichun Gu, Juan Li, Xiaoyan Liu, Xiaofan Wu, Yi Han, Jun Pu   +6 more
doaj   +1 more source

Response to bosentan in children with pulmonary hypertension [PDF]

Heart, 2006
To describe an early experience of treating 40 children with the dual endothelin receptor antagonist bosentan, which is known to be safe and effective in adults with pulmonary hypertension (PH).In this retrospective, observational study the UK Service for Pulmonary Hypertension for children treated 40 children with bosentan, 20 with idiopathic ...
S Maiya, Sheila G. Haworth, Alison A. Hislop, Yvette Flynn   +3 more
openaire   +3 more sources

Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research

British Journal of Clinical Pharmacology, EarlyView.
Aerospace medicine required controlled terrestrial models to investigate influences of altered atmosphere conditions, such as hypoxia, on human health and performance. These models could potentially be expanded to encompass disease conditions or treatment targets regulated through hypoxia or hypercapnia.
Titiaan E. Post, Cayla Denney, Adam Cohen, Jens Jordan, Ulrich Limper   +4 more
wiley   +1 more source

Bosentan for high-risk outpatients with COVID-19 infection: a randomized, double blind, placebo-controlled trialResearch in context

EClinicalMedicine, 2023
Summary: Background: The endothelium is supposedly activated and damaged in COVID-19 because of endothelin-1 over-secretion. This study evaluates the effect of bosentan as an endothelin receptor blocker on the progression of disease in high-risk ...
Shaahin Shahbazi, Zahra Vahdat Shariatpanahi, Erfan Shahbazi   +2 more
doaj  

Advancing antihypertensive drug development

British Journal of Pharmacology, EarlyView.
Hypertension affects more than a billion individuals worldwide and remains a major cause of cardiovascular morbidity and mortality. Despite advances in therapies, optimal blood pressure control remains elusive for many patients because of treatment resistance, adverse effects, and adherence challenges.
Fay Pu, Yanrong Liu, Fozia Zahir Ahmed, Xin Wang, Darren Green, Hongyuan Zhang   +5 more
wiley   +1 more source

Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non‐diabetic chronic kidney disease

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To evaluate whether type 2 diabetes status modifies the efficacy and safety of combining zibotentan (zibo), a selective endothelin receptor antagonist, and dapagliflozin (dapa) compared to placebo plus dapagliflozin in individuals with chronic kidney disease (CKD).
Victor Wasehuus, J. David Smeijer, Phil Ambery, Peter J. Greasley, Emma Wijkmark, David C. Wheeler, Peter Rossing, Hiddo J. L. Heerspink   +7 more
wiley   +1 more source

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Canadian Respiratory Journal, 2018
Background and objective: Two endothelin receptor antagonists (ETRAs), bosentan and ambrisentan, are approved for patients with pulmonary arterial hypertension (PAH).
Su-Gang Gong, Lan Wang, Bigyan Pudasaini, Ping Yuan, Rong Jiang, Qin-Hua Zhao, Jing He, Rui Zhang, Wen-hui Wu, Jin-Ming Liu, Cai-cun Zhou   +10 more
doaj   +1 more source